Science-to-Venture & Strategic Partnerships

Early-stage technology ventures often succeed because a very small number of exceptional people carry almost everything themselves: scientific vision, product judgement, hiring, customer relationships and the most important decisions. That intensity is a strength at the beginning. But if every important question continues to return to the founders, growth eventually amplifies dependency rather than capability.

I work with founders on the transition from an exceptional founder-led venture to an organization capable of scaling without losing what made it exceptional in the first place. That means deciding which responsibilities must move outward, where new leadership capability is needed, how to attract substantially stronger people, which structures should be introduced — and which should deliberately be resisted because they add bureaucracy before they add value.

This is not generic start-up coaching and not a playbook for professionalizing everything as quickly as possible. It is about identifying the few changes that allow a science- or technology-driven venture to grow beyond its founders while protecting speed, ambition, technical excellence and the ability to make unusually good decisions.

Typical questions may include

• Which responsibilities still genuinely require the founders — and which have become founder dependencies that now limit the company's growth?
• Which leadership capabilities and exceptional hires do we need next if the organization is to become substantially stronger rather than simply larger?
• Which processes and structures will help us scale — and which would introduce complexity, slow decisions or dilute the entrepreneurial edge too early?
• What must remain uncompromisingly part of the company's identity as we grow — and where do the founders themselves need to change for the next stage to become possible?

Science-driven founders are often deeply attached to the technology they have created. That passion is essential, but it can also become a trap: teams continue improving scientific sophistication while gradually losing sight of the actual customer problem, the level of performance the market really requires, or the simplicity needed for adoption.

Throughout my career, I have seen many founders fall into precisely this trap and struggle to commercialize an initially strong idea. I have also seen ventures make the transition successfully by following a small number of fundamental principles: understanding what customers truly value, separating scientific differentiation from unnecessary complexity, knowing when further research creates real advantage, and building product and technology roadmaps around the same commercial objective.

I deliberately work with only a limited number of ventures, allowing me to become deeply engaged with each company's technology, internal dynamics and concrete needs rather than offering advice from a distance.

This is not generic startup coaching or standard business-angel advice. It is about identifying where scientific excellence can create a defensible market advantage — and avoiding the common mistake of building an increasingly impressive technology without building an increasingly valuable company.

Typical questions may include

• Which part of our scientific or technological advantage will actually matter to customers — and which parts are primarily interesting to us as researchers or engineers?
• What still has to change before our technology becomes sufficiently robust, scalable and usable for the market we want to enter?
• Where should we continue pushing the research frontier — and where should we stop optimizing and turn what we already have into a product?
• How do we preserve a genuine technological advantage while simplifying the solution enough to achieve adoption, scalability and commercial focus?

For science- and technology-driven ventures, partnerships can provide capabilities that would be difficult or slow to build alone: access to customers, complementary technology, data, infrastructure, distribution, scientific expertise or credibility in a new market. But the existence of a potential partner does not make a partnership strategically useful. The decisive question is whether both sides create something together that materially strengthens the company's long-term position.

I work with founders to assess partnerships from that perspective: what each side genuinely contributes, whether incentives remain aligned over time, which dependencies are being created, what should remain proprietary, and whether the partnership accelerates the company's strategy or quietly begins to define it. Especially for smaller ventures, knowing when to decline an attractive-looking opportunity can be as important as securing the right one.

I can draw on an extensive international network across founders, investors, technology companies, research institutions and public-sector organizations where relevant to the work. The objective is not to act as an introduction service, but to use that perspective and network selectively when it can strengthen the company's options or help evaluate a potential path.

This is not partnership brokering and not about maximizing the number of collaborations. It is about identifying the few relationships that can genuinely accelerate the venture while protecting its independence, technological edge and long-term strategic value.

Typical questions may include

• Which capabilities, market access or assets should we build ourselves — and where could the right partner accelerate us substantially?
• What does each side genuinely contribute to this partnership, and are the incentives likely to remain aligned as the company grows?
• Which technologies, data, intellectual property or strategic capabilities must remain under our own control even if sharing them would make a partnership easier today?
• Which apparently attractive partnerships should we decline because they create dependency, consume focus or constrain more valuable options later?

Deep-tech companies often face a different financing logic from conventional startups. Scientific and technological milestones may take longer, commercial proof can emerge unevenly, and investors need to understand not only the size of the opportunity but also why the underlying technology creates an advantage that can endure. Raising the wrong capital, at the wrong time or against the wrong expectations can create pressure that ultimately weakens the company rather than accelerates it.

I work with founders on the strategic questions behind financing: which milestones should be reached before raising the next round, how technological progress and commercial traction should reinforce one another, what kind of investor is appropriate for the company's stage and ambition, and how to communicate the scientific advantage without either oversimplifying it or turning the investment case into a research presentation.

Where useful, I can also draw on my international network and experience with founders, investors and technology ecosystems to understand different perspectives around a financing decision. The objective is not simply to optimize the next round, but to make sure that capital strengthens the company's ability to pursue its long-term opportunity.

This is not fundraising brokerage and not investor matchmaking. It is strategic work on how, when and from whom a science-driven venture should raise capital — while preserving ambition, independence and the ability to make the right long-term decisions.

Typical questions may include

• Which scientific, technological and commercial milestones should we reach before raising the next round — and which can reasonably come afterwards?
• What type of investor best matches our stage, technological ambition and expected path to market?
• How do we explain a genuinely complex scientific advantage in a way investors can understand without overselling what the technology can currently deliver?
• Which financing choices or investor expectations could constrain strategically important options later — even if they make the next round easier today?